Journal of Alzheimer's disease : JAD · 2015
No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chiam Justin Tao Wen, Lunnon Katie, Voyle Nicola, Proitsi Petroula, Coppola Giovanni, Geschwind Daniel, Nelson Sally, Johnston Caroline, Soininen Hilkka, Kłoszewska Iwona, Mecocci Patrizia, Tsolaki Magda, Vellas Bruno, Hodges Angela, Lovestone Simon, Newhouse Stephen, Dobson Richard James Butler, Kiddle Steven John, Sattlecker Martina
Аннотация
BACKGROUND: There is an urgent need to discover Alzheimer's disease (AD) biomarkers that are both easily measured and reliable. Research into blood-based biomarkers for AD using transcriptomics and proteomics has been an attractive and promising area of research. However, to date researchers have not looked into the possibility of AD medication being a confounding factor in these studies.
OBJECTIVE: This study explored whether acetylcholinesterase inhibitors (AChEIs), the main class of AD medication, are a confounding factor in AD blood biomarker studies.
METHODS: The most promising blood transcriptomic and proteomic biomarkers from two recent studies were analyzed to determine if they were differentially expressed between AD subjects on AChEIs and subjects that were not.
RESULTS: None of the gene or protein biomarkers analyzed were found to be significantly altered between subjects in either group.
CONCLUSION: This study found no evidence that AChEIs are a confounding factor in these published AD blood biomarker studies. Further work is needed to confirm that this is also the case for other proposed biomarkers.
OBJECTIVE: This study explored whether acetylcholinesterase inhibitors (AChEIs), the main class of AD medication, are a confounding factor in AD blood biomarker studies.
METHODS: The most promising blood transcriptomic and proteomic biomarkers from two recent studies were analyzed to determine if they were differentially expressed between AD subjects on AChEIs and subjects that were not.
RESULTS: None of the gene or protein biomarkers analyzed were found to be significantly altered between subjects in either group.
CONCLUSION: This study found no evidence that AChEIs are a confounding factor in these published AD blood biomarker studies. Further work is needed to confirm that this is also the case for other proposed biomarkers.